ArticleRheumatology (Oxford, England)2025
Aquaporin-4 downregulation in dysphagic patients with idiopathic inflammatory myopathies: myofiber vulnerability and inflammation drivers.
Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesTo evaluate whether the impairment of aquaporin-4 (AQP4), a water channel protein important for muscle function, may be associated with dysphagia in idiopathic inflammatory myopathies (IIMs). Swallowing muscle inflammation in IIM has been documented in case reports, but direct correlations with limb muscles impairment are lacking.
methodsAQP4 was immunolocalized in limb muscle biopsies. The percentage of AQP4 expressing myofibers was compared in IIM patients with and without dysphagia, and healthy controls, and correlated with muscular strength, creatine kinase level and myositis damage index. Additionally, myosin heavy chain (fast and neonatal), cluster of differentiation 68 (CD68) and matrix metalloproteinase-2 (MMP2) were immunolocalized with sarcolemma AQP4 to evaluate whether an increase in innate immunity and extracellular matrix degradation were reflected in the modified AQP4 expression.
resultsAQP4 immunostaining was significantly decreased in myofibers of dysphagic patients compared with normophagic patients and controls. Moreover, although both IIM groups had CD68-positive cells surrounding AQP4-negative myofibers, only in dysphagic patients AQP4-negative myofibers surrounded by CD68-positive and MMP2-positive cells were significantly increased, suggesting that inflammation from blood vessels and inflammatory cells affects AQP4 immunolocalization.
conclusionMyofiber hypotrophy appears to be due to inflammation from CD68-positive and MMP2-positive cells, whose activity disrupts the extracellular matrix and may detach AQP4 from the sarcolemma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.